Kyung Ran Park1, Chang Geol Lee2, Yolanda D Tseng3, Jay J Liao3, Suresh Reddy1, Eduardo Bruera1, Sriram Yennurajalingam4. 1. Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA. 2. Department of Radiation Oncology, Yonsei University College of Medicine, Yonsei Cancer Center, Seoul, Republic of Korea. 3. Department of Radiation Oncology, University of Washington, Seattle, USA. 4. Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: syennu@mdanderson.org.
Abstract
PURPOSE: To investigate the utilization of palliative radiation therapy (RT), predictors for the use of RT, and symptom palliation following RT during the last 30 days of life through systemic review of literature. MATERIALS/ METHODS: A systematic search of available medical literature databases was performed on patients receiving palliative RT in the last 30 days of life. A total of 18 studies were evaluated. RESULTS: The overall palliative RT utilization rates during the last month of life were in the range of 5-10% among patients who died of cancer and 9-15.3% of patients who received palliative RT. The most commonly used regimen was 30 Gy in 10 fractions (36-90%). Single fraction RT utilization ranged from 0% to 59%. ECOG performance status 3-4 was significantly associated with patients receiving RT in the last 30 days of life and shorter survival. Twenty-six percent of patients who survived less than 1 month were reported to show symptom palliation following RT. CONCLUSION: Palliative RT was performed in approximately 10% of patients who died of cancer near their end of life, with the most commonly used regimen of 30 Gy in 10 fractions. This study suggests that greater use of shorter or single fraction regimens may be beneficial, especially in patients with poor performance status.
PURPOSE: To investigate the utilization of palliative radiation therapy (RT), predictors for the use of RT, and symptom palliation following RT during the last 30 days of life through systemic review of literature. MATERIALS/ METHODS: A systematic search of available medical literature databases was performed on patients receiving palliative RT in the last 30 days of life. A total of 18 studies were evaluated. RESULTS: The overall palliative RT utilization rates during the last month of life were in the range of 5-10% among patients who died of cancer and 9-15.3% of patients who received palliative RT. The most commonly used regimen was 30 Gy in 10 fractions (36-90%). Single fraction RT utilization ranged from 0% to 59%. ECOG performance status 3-4 was significantly associated with patients receiving RT in the last 30 days of life and shorter survival. Twenty-six percent of patients who survived less than 1 month were reported to show symptom palliation following RT. CONCLUSION: Palliative RT was performed in approximately 10% of patients who died of cancer near their end of life, with the most commonly used regimen of 30 Gy in 10 fractions. This study suggests that greater use of shorter or single fraction regimens may be beneficial, especially in patients with poor performance status.
Authors: Michael Oertel; Renate Schmidt; David Rene Steike; Hans Theodor Eich; Philipp Lenz Journal: Strahlenther Onkol Date: 2022-08-11 Impact factor: 4.033
Authors: Miriam Vázquez; Manuel Altabas; Diana C Moreno; Abraham A Geng; Santiago Pérez-Hoyos; Jordi Giralt Journal: Front Oncol Date: 2021-04-23 Impact factor: 6.244
Authors: T S Lewis; J A Kennedy; G J Price; T Mee; D K Woolf; N A Bayman; C Chan; J H Coote; C Faivre-Finn; M A Harris; A M Hudson; L S Pemberton; A Salem; H Y Sheikh; H B Mistry; D C P Cobben Journal: Clin Oncol (R Coll Radiol) Date: 2020-06-26 Impact factor: 4.126
Authors: Susan Y Wu; Emily Yee; Harish N Vasudevan; Shannon E Fogh; Lauren Boreta; Steve E Braunstein; Julian C Hong Journal: JAMA Netw Open Date: 2021-07-01
Authors: Haley K Perlow; Vincent Cassidy; Benjamin Farnia; Deukwoo Kwon; Adam W Awerbuch; Stephanie Ciraula; Scott Alford; Jacob Griggs; Joseph A Quintana; Raphael Yechieli; Stuart E Samuels Journal: Adv Radiat Oncol Date: 2018-09-14